It’s a small world

To understand the full scope of a condition, pharma needs to appreciate the full tapestry of the patient experience. The challenge for industry in the realm of rare diseases, however, is to meaningfully engage with patients and convince them that they are an essential part of the research equation
Changing tack

Think the old product launch playbook is still relevant? Think again.
The strongest link?

Jennifer Bradford and Matthew Metherell consider the success and potential of artificial intelligence in clinical research and the impact of machine learning on clinical trials

News

View all

EU nod for Bayer's Vitrakvi

European regulators have cleared Bayer's Vitrakvi (larotrectinib) as a treatment for solid tumours displaying an NTRK gene fusion.

23rd September 2019

NICE calls for further research on tinnitus management

Healthcare professionals should develop a management plan with the patient

23rd September 2019

Hospital admissions increase 28% in ten years

The figures should serve as a "wake-up call', says the BMJ.

23rd September 2019

Bluebird reveals positive gene therapy data

The therapy targets cerebral adrenoleukodystrophy (CALD), the most severe manifestation of adrenoleukodystrophy (ALD), a rare metabolic disorder.

23rd September 2019

Xospata leads latest CHMP recommendations

The committee has recommended seven medicines for approval at its September 2019 meeting.

20th September 2019

Web Exclusives

View all

Keep on preparing for Brexit

How can the pharma industry best prepare for Brexit?

Engaging with patient advocacy groups

Harrison Gaiger, marketing manager of the Research Partnership, says working with patient advocacy groups is key to conducting effective rare disease research

Optimising pharma suppliers' eCommerce

Tips from Sam Rutley on how pharmaceutical suppliers can optimise their eCommerce offering

Wake up to the opportunities of longer living

George MacGinnis, challenge director of healthy ageing at UKRI, says businesses need to wake up to the opportunities of our longer lives

Magazine

View more from the latest edition

Transforming mental health services

Paul Midgley, of Wilmington Healthcare, explores the NHS Long Term Plan’s strategy for tackling mental health conditions

To understand the full scope of a condition, pharma needs to appreciate the full tapestry of the patient experience. The challenge for industry in the realm of rare diseases, however, is to meaningfully engage with patients and convince them that they are an essential part of the research equation

The liberation of patient data

Aiden Flynn explores how the collection and analysis of real-world patient data can be an invaluable asset in clinical development

Technology in focus: the Liqui-Pellet

University of Sussex researcher Matthew Lam talks to PharmaTimes about a new oral dosage technology developed to help tackle bioavailability challenges

Changing tack

Think the old product launch playbook is still relevant? Think again.

Making sense of it

As life sciences companies’ international ambitions grow, and global regulatory scrutiny in parallel, managing translated content is becoming ever more complex. So the promise of neural machine learning as a potential solution is appealing. But just how far can the technology go in reducing workloads and improving accuracy and turnaround times?

The promise of gene editing

Christopher Vakulskas says the rapid progress seen in gene editing is exciting, but there are still challenges in the field to overcome if its full potential is to be reached

The strongest link?

Jennifer Bradford and Matthew Metherell consider the success and potential of artificial intelligence in clinical research and the impact of machine learning on clinical trials

Thought Leadership

View all

Understanding customer needs in the fast-changing NHS

Simon Grime, of Wilmington Healthcare, explains how pharma can navigate the new integrated care landscape using an intelligence-led approach

Releasing the potential of real world evidence

Janssen believes RWE could realise an efficient, personalised and truly patient-centric healthcare system

New frontiers

Tom O'Leary considers how the Internet of Medical Things (IoMT) is evolving the patient role in pharma

A smart and healthy approach to defending the bottom line

New smart building technologies are helping pharmaceutical companies enhance productivity without compromising on compliance or quality. However, to maximise the available opportunities, companies need to choose the right technology providers, explains Adam Chapman, Vertical Sales Director – Life Sciences (Europe) at Honeywell Building Solutions.